AIMEDBIO
IR
ENG
KOR
ABOUT US
Overview
Leadership
Corporate Governance
R&D
AimedBio’s Drug Development
P-ADC™
Pipeline
IR
Disclosure
Stock
Financial Information
PR
Notice
Press Release
Data Room
CAREERS
Our Culture
Recruitment Process
Job Opportunities
Disclosure
70 posts
NO.
Title
Date
Author
50
[Corrected description]Quarterly Report (2026.03)
2026-05-15
에임드바이오
49
Quarterly Report (2026.03)
2026-05-15
에임드바이오
48
Material Management Information related to Judgment of Investment (ODS025 기술이전계약 관련 연구개발비 수령)
2026-05-06
에임드바이오
47
Report on the Grant of Stock Options
2026-03-27
에임드바이오
46
Outcomes of Annual Meeting of Shareholders
2026-03-27
에임드바이오
45
Forecast on Business Performance according to Consolidated Financial Statements(Fair Disclosure)
2026-03-26
에임드바이오
44
Annual Report (2025.12)
2026-03-19
에임드바이오
43
Submission of Audit Report
2026-03-19
에임드바이오
42
Report on status of specific securities, etc. owned by executives and major shareholders
2026-03-17
인터베스트
41
Report on significant holdings of stocks, etc. (Short form)
2026-03-17
인터베스트
[Corrected description]Quarterly Report (2026.03)
에임드바이오
2026-05-15
Quarterly Report (2026.03)
에임드바이오
2026-05-15
Material Management Information related to Judgment of Investment (ODS025 기술이전계약 관련 연구개발비 수령)
에임드바이오
2026-05-06
Report on the Grant of Stock Options
에임드바이오
2026-03-27
Outcomes of Annual Meeting of Shareholders
에임드바이오
2026-03-27
Forecast on Business Performance according to Consolidated Financial Statements(Fair Disclosure)
에임드바이오
2026-03-26
Annual Report (2025.12)
에임드바이오
2026-03-19
Submission of Audit Report
에임드바이오
2026-03-19
Report on status of specific securities, etc. owned by executives and major shareholders
인터베스트
2026-03-17
Report on significant holdings of stocks, etc. (Short form)
인터베스트
2026-03-17
1
2
3
4
5